Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Completed · Phase 1/Phase 2
Conditions studied: Refractory Multiple Myeloma
In brief
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Giving bendamustine hydrochloride together with lenalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride and lenalidomide when given together with dexamethasone and to see how well they work in treating patients with relapsed multiple myeloma.
Key facts
- Study ID
- NCT01049945
- Run by
- Mayo Clinic
- People needed
- 70
- Starts
- 2010-02-01
- Expected to finish
- 2015-09-16
- Last updated by the study team
- 2020-02-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- Mayo Clinic in Florida — Jacksonville, Florida, United States
- University of Chicago — Chicago, Illinois, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Washington Universtiy School of Medicine — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.